{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:59:07Z","timestamp":1774396747316,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bulky residual tumor after external beam radiotherapy (EBRT) presents a major technical challenge for brachytherapy (BT) and is a significant prognostic risk factor in locally advanced cervical cancer (LACC). The use of chemotherapy combined with an immune checkpoint inhibitor to reduce tumor volume (TV) during the interval between EBRT completion and BT initiation has been rarely explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>We present two cases of stage IIIC1r cervical squamous cell carcinoma with residual tumors larger than 5 cm following EBRT. Patient characteristics, examination findings, laboratory and imaging data, treatment responses, and adverse events were recorded. After sequential treatment with albumin-bound paclitaxel plus cisplatin combined with zimberelimab, both patients achieved marked tumor volume reduction and subsequently underwent reduced-volume BT. Neither patient experienced recurrence at 36-month and 25-month follow-ups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sequential chemo-immunotherapy followed by reduced-volume BT may represent an alternative treatment option for patients with bulky residual disease after EBRT. Further clinical studies are warranted to validate the effectiveness of this combined regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1687247","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:16Z","timestamp":1763534116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful sequential chemo-immunotherapy and reduced-volume brachytherapy for bulky residual cervical tumor after external beam radiotherapy: two case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Lan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conghui","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingrao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra2404457","article-title":"Cervical cancer","volume":"392","author":"Tewari","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.06.022","article-title":"The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI","volume":"107","author":"Nam","year":"2007","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13014-021-01978-0","article-title":"Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer","volume":"17","author":"Chen","year":"2022","journal-title":"Radiat Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01096","article-title":"Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study","volume":"41","author":"Schmid","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.08.025","article-title":"Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03","volume":"190","author":"Choi","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113471","article-title":"Prognostic significance of tumor regression rate during concurrent chemoradiotherapy in locally advanced cervix cancer: analysis by radiation phase and histologic type","volume":"9","author":"Kang","year":"2020","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.04.022","article-title":"Nomogram predicting overall survival in patients with locally advanced cervical cancer treated with radiochemotherapy including image-guided brachytherapy: A retro-EMBRACE study","volume":"111","author":"Sturdza","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-02000-6","article-title":"Dose-effect relationship between dose-volume parameters of residual gross tumor volume and clinical prognosis in MRI-guided adaptive brachytherapy for locally advanced cervical cancer: a single-center retrospective study","volume":"199","author":"Ke","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934110","article-title":"The prognostic value of tumor size, volume and tumor volume reduction rate during concurrent chemoradiotherapy in patients with cervical cancer","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3892\/mco.2021.2304","article-title":"Radiosensitization using hydrogen peroxide in patients with cervical cancer","volume":"15","author":"Hu","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"B14","article-title":"New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms","volume":"19","author":"Ogawa","year":"2008","journal-title":"Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004705","article-title":"Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study","volume":"33","author":"Xia","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.12.015","article-title":"Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder","year":"2005","journal-title":"Radiother Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","article-title":"Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology","volume":"78","author":"Potter","year":"2006","journal-title":"Radiother Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.04.037","article-title":"Distant metastasis after chemoradiation and image guided adaptive brachytherapy in locally advanced cervical cancer","author":"Knoth","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.036","article-title":"Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer","volume":"76","author":"Mayr","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.09.036","article-title":"Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01","volume":"147","author":"Lee","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000837","article-title":"The predictive value of tumor size, volume, and markers during radiation therapy in patients with cervical cancer","volume":"27","author":"Lee","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.06.014","article-title":"Tumor shrinkage during chemoradiation in locally advanced cervical cancer patients: prognostic significance, and impact for image-guided adaptive brachytherapy","volume":"102","author":"Schernberg","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.radonc.2015.03.007","article-title":"Cervical cancer outcome prediction to high-dose rate brachytherapy using quantitative magnetic resonance imaging analysis of tumor response to external beam radiotherapy","volume":"115","author":"Minkoff","year":"2015","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.01.010","article-title":"Clinical feasibility of combined intracavitary\/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem\/ring applicator in situ and virtual preplanning of the interstitial component","volume":"107","author":"Fokdal","year":"2013","journal-title":"Radiother Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.03.020","article-title":"Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study","volume":"120","author":"Fokdal","year":"2016","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.12.019","article-title":"Ring versus ovoids and intracavitary versus intracavitary-interstitial applicators in cervical cancer brachytherapy: results from the EMBRACE I study","volume":"106","author":"Serban","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17340","article-title":"Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour","volume":"130","author":"Lu","year":"2023","journal-title":"BJOG"},{"key":"B29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13014-024-02536-0","article-title":"3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes","volume":"19","author":"Lu","year":"2024","journal-title":"Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2023.02.002","article-title":"3D printing in brachytherapy: A systematic review of gynecological applications","volume":"22","author":"Fahimian","year":"2023","journal-title":"Brachytherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.04.005","article-title":"Developing next-generation 3-dimensional printing for cervical cancer hybrid brachytherapy: A guided interstitial technique enabling improved flexibility, dosimetry, and efficiency","volume":"117","author":"Marar","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3892\/ol.2021.12707","article-title":"Analysis of radiotherapy-induced alteration of CD8(+) T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma","volume":"21","author":"Mori","year":"2021","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1687247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:17Z","timestamp":1763534117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1687247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1687247"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1687247","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1687247"}}